メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:神経障害性疼痛

Market Spotlight: Neuropathic Pain

発行 Datamonitor Healthcare 商品コード 573564
出版日 ページ情報 英文 36 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.20円で換算しております。
Back to Top
注目市場の分析:神経障害性疼痛 Market Spotlight: Neuropathic Pain
出版日: 2018年03月09日 ページ情報: 英文 36 Pages
概要

当レポートでは、神経障害性疼痛市場について調査分析し、主要パイプライン・上市薬、臨床試験、規制動向、特許情報、罹患率の10ヶ年予測、ライセンス・買収取引、収益予測など、体系的な情報を提供しています。

要点

疾患の背景

  • サブタイプ

治療

  • 抗うつ薬
  • 抗てんかん薬
  • カンナビノイド
  • オピオイド
  • 局所療法

疫学

パイプライン薬

上市薬

  • 承認:国別

規制動向

ライセンス・資産買収取引

親特許

収益機会

臨床試験情勢

  • スポンサー:状況別
  • スポンサー:フェーズ別

参考文献

  • 処方箋情報

付録

目次
Product Code: DMKC0179877

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2016, there were 385.0 million prevalent cases of neuropathic pain in adults aged 20 years and older worldwide, and forecasts that number to increase to 431.3 million prevalent cases by

2025. Asia is estimated to have had the largest number of prevalent cases in 2016, but the lowest prevalence proportion (96.4 million cases; 3.20%).

The majority of industry-sponsored drugs in active clinical development for neuropathic pain are in Phase I, with just one therapy in Phase III.

Therapies in mid- and late-stage development for neuropathic pain focus on a variety of targets such as opioid receptors, sodium channels, TRPV1, and NMDA receptors. The majority of pipeline drugs in mid- and late-stage development for neuropathic pain are administered orally, with the remainder including intravenous and topical formulations.

Sodium channel antagonists Carbatrol (carbamazepine; Shire) and Tegretol (carbamazepine; Novartis), Pfizer's calcium channel agonist Lyrica (pregabalin), and Acorda's transient receptor potential vanilloid receptor 1 agonist Qutenza (capsaicin) are the only marketed drugs available for neuropathic pain. These marketed drugs are administered via the oral route, except for Qutenza, which is available as a topical formulation.

There were 21 licensing and asset acquisition activities involving neuropathic pain drugs during 2012-17, seven of which occurred in

2015. The exclusive licensing agreement in 2015 between Depomed and Janssen for the acquisition of US rights to Nucynta for $1.05bn was the largest deal during 2012-17.

Lyrica's sales ranked highest among drugs available for neuropathic pain during 2012-16, and revenues are expected to remain high until its patent expiry at the end of

2018. The distribution of clinical trials across Phase I-IV indicates that the majority of trials have been in the early and mid-phases of development, with 68% of trials in Phase I-II, and 32% in Phase III-IV.

The US has a substantial lead in the number of neuropathic pain clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Pfizer has by far the highest number of completed clinical trials for neuropathic pain, and has also had the highest number of trials for neuropathic pain at all phases of development.

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Subtypes

8 TREATMENT

8 Antidepressants

8 Antiepileptics

8 Cannabinoids

8 Opioids

9 Topical or focal therapies

10 EPIDEMIOLOGY

14 MARKETED DRUGS

16 Approvals by country

19 PIPELINE DRUGS

26 KEY UPCOMING EVENTS

27 LICENSING AND ASSET ACQUISITION DEALS

27 Lexicon Paying Bristol To Take Over Neuropathic Pain Candidate

28 PARENT PATENTS

29 REVENUE OPPORTUNITY

30 CLINICAL TRIAL LANDSCAPE

31 Sponsors by status

32 Sponsors by phase

34 BIBLIOGRAPHY

34 Prescription Information:

35 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of neuropathic pain, 2016-25
  • 19 Figure 2: Pipeline drugs for neuropathic pain in the US
  • 20 Figure 3: Pipeline drugs for neuropathic pain, by company
  • 20 Figure 4: Pipeline drugs for neuropathic pain, by drug type
  • 21 Figure 5: Pipeline drugs for neuropathic pain, by drug classification
  • 26 Figure 6: Key Upcoming Events
  • 27 Figure 7: Licensing and asset acquisition deals in neuropathic pain, 2013-18
  • 28 Figure 8: Parent patents in neuropathic pain
  • 30 Figure 9: Clinical trials in neuropathic pain
  • 30 Figure 10: Top 10 drugs for clinical trials in neuropathic pain
  • 31 Figure 11: Top 10 companies for clinical trials in neuropathic pain
  • 31 Figure 12: Trial locations in neuropathic pain
  • 32 Figure 13: Neuropathic pain trials status
  • 33 Figure 14: Neuropathic pain trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of neuropathic pain, 2016-25
  • 13 Table 2: Prevalence proportions of neuropathic pain, 2016-25
  • 15 Table 3: Marketed drugs for neuropathic pain
  • 17 Table 4: Approvals by country for neuropathic pain
  • 22 Table 5: Pipeline drugs for neuropathic pain in the US
  • 29 Table 6: Historical global sales, by drug ($m), 2012-16
  • 29 Table 7: Forecasted global sales, by drug ($m), 2017-22

 

Back to Top